Resource Isis Pharmaceuticals, Inc.. Acceptance of initial regulatory filings for BMS-PCSK9Rx triggers $6M milestone payment to Isis Pharmaceuticals Isis Pharmaceuticals, Inc. announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Organization linked to the acceptance of initial regulatory filings to begin Phase 1 clinical research for BMS-PCSK9Rx. BMS-PCSK9Rx can be an antisense medication that arose from the ongoing collaboration between Bristol-Myers Squibb and Isis to recognize antisense medicines targeting PCSK9 to lessen low-density lipoprotein cholesterol.Bivalirudin was associated with a lower death rate from any trigger than was heparin , as well as a lower rate of death from cardiac causes . There have been no significant variations between the bivalirudin group and the heparin group in the rates of myocardial infarction, which contributed at least two thirds of the events to both coprimary end points , and stroke . The price of definite stent thrombosis was higher in the bivalirudin group than in the heparin group , whereas the rate of definite or probable events did not differ significantly .